Medrx Co

Medrx Co ROE

The Return on Equity (ROE) of Medrx Co (4586.T) as of Nov 21, 2026 is -45.75 %. In the previous year, Return on Equity (ROE) was -37.21 % — a change of 22.94% (lower).

ROE

-45.75 %

YoY

22.94%

Last updated:

In 2025, Medrx Co's return on equity (ROE) was -45.75 %, a 22.94% increase from the -37.21 % ROE in the previous year.

The Medrx Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-59.50 JPY
Jan 1, 2019
-84.15 JPY
Jan 1, 2020
-51.90 JPY
Jan 1, 2021
-54.20 JPY
Jan 1, 2022
-91.63 JPY
Jan 1, 2023
-48.51 JPY
Jan 1, 2024
-37.21 JPY
Jan 1, 2025
-45.75 JPY
The Medrx Co ROE history
YEARROEYoY
-45.75 %+22.94%
-37.21 %-23.29%
-48.51 %-47.05%
-91.63 %+69.06%
-54.20 %+4.42%
-51.90 %-38.32%
-84.15 %+41.43%
-59.50 %+36.85%
-43.48 %-13.44%
-50.23 %+58.55%
-31.68 %+9.52%
-28.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Medrx Co's Return on Equity (ROE)

Medrx Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Medrx Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Medrx Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Medrx Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Medrx Co stock

Return on Equity (ROE) of Medrx Co is -45.75 % in 2025.

Return on Equity (ROE) of Medrx Co changed from -37.21 % to -45.75 %, representing a 22.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Medrx Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medrx Co

All Key Metrics — Medrx Co